SLC5A2 and chronic kidney disease: This is often achieved through appropriate control of modifiable risk factors, dietary and lifestyle related, optimization of CKD medications such as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (15–17), and more recently sodium glucose cotransporter-2 (SGLT2) inhibitors (18, 19).